- Japan, South Korea End the Week on a High Note
- Bank of Japan Set to Downgrade View on Economy
- China's Economy Slowed in Q1 But Rebound on Horizon
- Chevron Expects Sharply Lower First-Quarter Profit
- This Is Why Buffett Says It's 'Great Time' to Be in Banking
- US Flexes Muscle in Standoff with Somali Pirates
- How Ford Avoided the Meltdown that Hit GM, Chrysler
- US Economic 'Free-Fall' to End in Months: Summers
- Wells Fargo CFO: Wachovia Merger Behind Big Profits
- Your Trades for Next Week
- Mad Mail: How Did Wells Fargo Beat the Street?
- Lightning Round: Morgan Stanley, Smuckers, W&T Offshore and More
- Lightning Round OT: Halliburton, Cliffs Natural and More
- Executive Decision: Chattem CEO Zan Guerry
- Sell Block: Life Insurers Escape Their Own Demise
- Cramer: Healthy Banks Key to Market Move
- Pops & Drops: GE, Toyota, Abercrombie, Dell...
- Wells Fargo Leads Comeback Rally
Text Size 
A study of Pfizer's Sutent was halted early after the medicine delayed progression of a rare form of pancreatic cancer affecting tens of thousands of people globally, including Apple [AAPL
Loading...
()
] CEO Steve Jobs.
An independent safety board monitoring the late-stage study recommended halting it after concluding that patients on Sutent stayed free of disease progression for longer than those on placebo plus best supportive care, Pfizer said on Thursday.
Given the clearly favorable trend, patients who took Sutent in the trial will be allowed to continue doing so, and those who were given placebos will now have the option of taking the drug instead.
Patients in the study had advanced pancreatic islet cell tumors, also known as neuroendocrine cancer. It occurs in specialized cells of the pancreas that secrete a variety of hormones, including insulin and enzymes involved in digestion.
Other types of pancreatic cancer occur in ducts of the pancreas—small tubes that transport digestive enzymes produced in the pancreas to the small intestine.
"This form of pancreatic cancer involves only about 5 percent of all pancreatic cancer cases, and grows and spreads more slowly'' than other types of pancreatic cancer, said Mace Rothenberg, a senior Pfizer research executive.
But when surgery to remove the cancer is not possible, or when cancer returns after surgery, Rothenberg said life expectancy is only several years, and patients can experience difficult symptoms, such as life-threatening high levels of insulin and stomach ulcers.
Sutent, which had fourth-quarter sales of $220 million, is currently approved for treating advanced kidney cancer as well as gastrointestinal tract tumors.
Pfizer is also testing the medicine in late-stage studies against cancers of the breast, lungs, colon, prostate and liver.
Shares of Pfizer [PFE
Loading...
()
] were up over 6 percent in afternoon trading, amid a 3 percent rise in the American Stock Exchange Pharmaceutical Index of large U.S. and European drugmakers.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes